Yazar "Bolukbasi, Y." seçeneğine göre listele
Listeleniyor 1 - 12 / 12
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Carcinoma of breast in males in Turkey: a Turkish oncology group study(Amer Assoc Cancer Research, 2009) Bolukbasi, Y.; Kucucuk, S.; Aydin, A.; Yetmen, O.; Haydaroglu, A.Öğe Do we overtreat or undertreat the axillary region in lymph node-positive breast cancer patients?(Elsevier Science Inc, 2008) Celik, O. Karakoyun; Hoca, S.; Bolukbasi, Y.; Olacak, N.; Haydaroglu, A.Öğe Erythropoietin and radiotherapy in lung cancer patients(Imprimatur Publications, 2009) Yurut-Caloglu, V.; Haydaroglu, A.; Ozkok, S.; Yalman, D.; Bolukbasi, Y.Purpose. To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT). Patients and methods: Thirteen consecutive patients were included. All of them had measurable tumor before RT 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 clays before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT Results: Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during R T was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034). Conclusion: rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.Öğe Evaluation of anxiety level during intracavitary brachytherapy applications in patients with gynecologic malignancy(Pergamon-Elsevier Science Ltd, 2005) Yalman, D.; Kamer, S.; Ozsaran, Z.; Celik, O.; Bolukbasi, Y.; Bildilk, O.; Haydaroglu, A.Öğe Evaluation of anxiety levels during intracavitary brachytherapy applications in women with gynecological malignancies(I R O G Canada, Inc, 2007) Kamer, S.; Ozsaran, Z.; Celik, O.; Bildik, O.; Yalman, D.; Bolukbasi, Y.; Haydaroglu, A.Purpose: To evaluate the anxiety levels of women treated for gynecological malignancies using intracavitary brachytherapy. Methods: Anxiety levels prior to and after intracavitary brachytherapy application and factors influencing anxiety levels were evaluated. Women were evaluated for quality of life and psychological status before each brachytherapy application using the Hospital Anxiety and Depression Scale (HADS). Scores were grouped as follows: 0-7 = normal, 8-10 = borderline, 11-21 = abnormal. Women were also questioned about other factors which could affect anxiety levels such as marital status, education level, number of pregnancies and prior surgical history. Results: Between January 2003 and August 2004, 146 women with a median age of 56 years were evaluated (range: 27-80). Eighty-six women had cervix uteri carcinoma and 63 had endometrial carcinoma. Sixty-seven women were premenopausal and 85 women were postmenopausal. The median pregnancy number was three (range = 0-10). Eighty-nine women had at least three children. Sixty-seven women had had previous operations. One hundred and twenty-five women were married and 24 women were unmarried or widowed. Before treatment, the anxiety scores were scored as normal in 49 (32%), borderline in 41 (28%), and abnormal in 59 (40%). Anxiety levels were lower in 69 women during the last application as compared with the pretreatment levels (p = 0.00). Marital status and pregnancy number showed a significant correlation with anxiety scores (p = 0.04). Age, level of education or having had a previous operation showed no significant correlation with anxiety level. Conclusion: These results indicate that intracavitary brachytherapy is associated with anxiety. Women need to be given detailed information before the brachytherapy application to reduce anxiety. Additional studies are needed to determine it.Öğe Expression of cyclin D1 and its relation with ER, PgR, C-erbB2, Ki-67, and p53 in breast cancer.(Amer Soc Clinical Oncology, 2010) Haydaroglu, A.; Demirci, S.; Demir, D.; Aydin, B.; Bolukbasi, Y.; Zekioglu, O.; Yeniay, L.; Ozdemir, N.; Gokmen, E.; Ylmaz, R.Öğe Outcome and pronostic factors in malignant Mixed Mullerian Tumours and endometrial stromal sarcomas: a rare cancer network study(Pergamon-Elsevier Science Ltd, 2009) Schick, U.; Bolukbasi, Y.; Abdah-Bortnyak, R.; Thariat, J.; Caglar, H.; Ozsaran, Z.; Loessl, K.; Zwahlen, D.; Villette, S.; Vees, H.Öğe Outcome and pronostic factors in malignant Mixed Mullerian Tumours and endometrial stromal sarcomas: a rare cancer network study(Pergamon-Elsevier Science Ltd, 2009) Schick, U.; Bolukbasi, Y.; Abdah-Bortnyak, R.; Thariat, J.; Caglar, H.; Ozsaran, Z.; Loessl, K.; Zwahlen, D.; Villette, S.; Vees, H.Öğe Postoperative radiotherapy in intermediate and high-risk Stage I endometrial cancer: analysis of prognostic factors and survival(I R O G Canada, Inc, 2008) Bolukbasi, Y.; Demirci, S.; Ozsaran, Z.; Yalman, D.; Hanhan, M.; Ozsaran, A.; Dikmen, Y.; Aras, A.Purpose: Patients with Stage IA Grade (G) III, Stage IB GII-III and Stage IC GI-II-III endometrial cancer who received postoperative adjuvant radiotherapy were evaluated in terms of local control, disease-free and overall survival rates and prognostic factors. Materials and Methods: Four hundred and three patients with Stage I endometrial cancer treated with radiotherapy from January 1990 to December 2003 at Ege University Faculty of Medicine Department of Radiation Oncology were reviewed retrospectively. According to our radiotherapy protocol patients with Stage IB G2 disease (149 patients) received only external radiotherapy and the remaining (254 patients) received both external radiotherapy and intracavitary brachytherapy. Results: Median age of the patients was 58 (range: 37-83). Nine patients (2.2%) had Stage IA, 196 (48.6%) had Stage IB and 198 (49.1%) had Stage IC disease. Histologic grade was 1 in 52 (12.9%) patients, 2 in 268 (66.5%) patients and 3 in 83 (20.6%) patients. Seventy-one (17.7%) patients had lymphovascular space invasion. Five-year locoregional relapse-free, distant-free, disease-free survival (DFS) and overall survival (OS) were 98.2%, 92.8%, 91.8% and 87.7%, respectively. In multivariate analysis, myometrial invasion and lymphovascular invasion were predictive factors for DFS and for OS prognostic factors were histologic type, myometrial invasion, and histologic grade. During radiotherapy 47.9% of the patients developed acute morbidity and 26.3% developed late morbidity, vaginal stenosis being the most frequent late morbidity. Conclusion: Postoperative adjuvant radiotherapy provides high locoregional control rates with acceptable toxicity in selected patients with Stage I endometrial carcinoma.Öğe Radiotherapy for brain metastases: Evaluation of 665 patients(Elsevier Science Inc, 2008) Yalman, D.; Bolukbasi, Y.; Yavas, F.; Ozkok, S.Öğe Results of hypofractionated whole brain radiotherapy (2x8 Gy) for patients with brain metastases from lung cancer(Zerbinis Medical Publ, 2011) Ozkok, S.; Bolukbasi, Y.; Akcay, C. Akay; Yalman, D.Purpose: To evaluate the clinical and radiologic response rates, toxicity and tolerability of 2x8 Gy whole brain radiotherapy (WBRT) in lung cancer patients with brain metastases (BM). Methods: WBRT was delivered to 126 lung cancer patients with BM during 2002-2006. External beam RT was delivered with a fraction dose of 8 Gy on the same day of each consecutive week Tumor and symptom response and toxicity were recorded at every follow-up. Recursive partitioning analysis (RPA) and the new Graded Prognostic Assessment (GPA) were used for analysis of overall survival (OS). Results: Twenty-three patients had small cell (SCLC) and 103 had non small cell lung cancer Pretreatment median Karnofsky performance score (KPS) was 70 (range 20-90). Clinical response rates were as follows: complete 31%; good partial 30.2%; partial 21.4%; stable 7.9%; and progressive 5.6%. Median palliation and survival duration was 57 and 80 days, respectively. Two- and 6-month survival rates (SR) were 59.5% and 25.4%, respectively. According to recursive partitioning analysis (RPA) 6-month SR for groups 1, 2 and 3 were 61.5, 41.6 and 33.9%, respectively (p=0.002). Six-month SR for the new Graded Prognostic Assessment (GPA) were: GPA 0-1, 7%; GPA 1.5-2.5, 34.2%; GPA 3, 25%; and GPA 3.5-4.0, 66.6% (p=0.0003). Conclusion: 2x8 Gy WBRT was found to be feasible. However the late morbidity of this schedule is unknown so its use could be restricted to patients with poor performance status, with a short life expectancy and/or social problems, unlikely to tolerate more protracted radiotherapy regimens.Öğe Vaginal Cuff Treatment and Subsequent Quality of Life Related Recommendations in Radiation Oncology Practice: Turkish Oncology Group Study Survey Report(Elsevier Science Inc, 2018) Bolukbasi, Y.; Yildiz, F.; Ozsaran, Z.; Onal, C.; Sezen, D.; Selek, U.
